

 **Mission of AABC**

The mission of the Alzheimer's Association® Business Consortium (AABC) is to advance Alzheimer's disease research and innovation in small- and medium-size biotechnology, diagnostics, medical device and contract research organizations.

AABC members work in areas of common interest pre-competitively to advance both the field of Alzheimer's research and the goals of its member organizations. They provide leadership and direction to the groups' areas of focus, which include, but are not limited to, collaborations, recognition and visibility, and knowledge and information sharing. AABC welcomes new member organizations who are aligned in their commitment to research and innovation. To express interest in joining, please email co-chairs Dr. Theresa Devins (tdevins@cogrx.com) or Dr. Paul Slowey (pds@4saliva.com), or Dr. Christopher Weber (cweber@alz.org), facilitator.

 **Welcome New Members**

AABC is growing! Welcome to:

- » **Atuka** is a neuroscience-focused preclinical CRO working to advance therapies for neurodegenerative disease. Founded in 2003 and based in Toronto, we've built our reputation as a world leader in Parkinson's disease research, with deep expertise in translational models of abnormal neural circuitry across rodent and non-human primate species. Our work pairs these models with clinically relevant endpoints — motor, cognitive and disease-modifying — and we're now actively extending these capabilities across the broader spectrum of neurological disease, including Alzheimer's. Alongside established models, we have a strong track record of developing novel ones where the science demands it, supporting evaluation of small molecules, biologics, gene therapies, and devices across symptomatic and disease-modifying approaches, with pharmacokinetic/pharmacodynamic and imaging readouts as needed. We're pleased to join the AABC and look forward to engaging with the membership and playing a real role in the consortium's efforts.
- » **Dr. Markus Krohn & Jonas Fischer, Caladrix Pty Ltd**
Caladrix is a precision-neurotherapeutics company developing orally delivered, small-molecule therapies designed to restore the brain's endogenous clearance systems in Alzheimer's disease. The company's clinical candidate C-001, is a multimodal activator of ABCC1, an efflux transporter with a well-characterized role in removing toxic proteins from the brain. C-001 has completed a human proof-of-concept study and is now advancing into a Phase 1b/2a clinical trial. Caladrix is built around a proprietary ABC transporter activation platform that underpins a broader pipeline of new chemical entities, each selected through human genetic validation and designed to generate independent, patentable drug classes. As part of the Alzheimer's Association Business Consortium, Caladrix aims to advance scalable, non-immunologic small-molecule therapies as a practical alternative to current antibody-based approaches, and to contribute translational insights in transporter biology, biomarker-driven trial design, and disease-modifying mechanisms to the broader research community.
- » **Five Lives**
Caring for our brain should be fun and engaging. Five Lives is a [FINGER based](#) brain health Digital Therapeutics (DTx) platform empowering people aged 50+ to enhance their cognitive resilience and "add life to years."
It spans two critical areas:
 - Prevention: Five Lives mobile app for healthy "worried-well" (200,000+ users), [combining clinically validated brain health assessment](#) and monitoring with personalised gamified lifestyle coaching and science backed brain games.
 - Therapy: Five Lives Care app, cognitive remediation for MCI patients and people living with memory difficulties. The app combines light physical activity (balance, cardio, stretching) together with brain training in a 30 min daily programme, to support cognition and quality of life.

Five Lives partners with Tier 1 academic institutions such as Oxford University, the FINGERS Brain Health Institute or APHP in France and works with clients in the Pharma (Eli Lilly, Biogen, Servier) and Insurance industries (Allianz, Generali).



Call for Papers: Circulating Biomarkers in Neurological Diseases, Precision Diagnostics

Submissions are now invited for a Special Topic in Clinical Therapeutics Journal, entitled Circulating Biomarkers in Precision Diagnostics: Advancing Disease Detection Across Clinical Disciplines, . This particular Special Topic is edited by Dr. Paul D. Slowey, one of our Co-Chairs of the AABC. Researchers working in Alzheimer's disease, neurodegeneration, early detection, and biomarker development are encouraged to submit manuscripts that advance precision diagnostics and improve disease detection across clinical care. Areas of interest include cell free DNA, cell free RNA, exosomes and other EVs, proteins, circulating tumor cells and others for the diagnosis or monitoring of any diseases from bodily fluids including blood, plasma, serum, CSF, urine, saliva and others. If interested, please e-mail Dr Slowey at info@4saliva.com

Imaginostics advances AADF-funded ADRD imaging study toward enrollment

Imaginostics is pleased to announce that its 96-subject imaging study in Alzheimer's Disease and Related Dementias, partially funded by the Alzheimer's Drug Discovery Foundation, is advancing toward first-patient enrollment at a U.S. clinical site. The study will use Imaginostics' QUTE-CE MRI platform to generate quantitative maps of microvascular structure, function, and blood-brain barrier leakage — a mechanism increasingly implicated in ADRD pathophysiology and in monitoring for amyloid-related imaging abnormalities (ARIA) in patients receiving anti-amyloid therapies such as lecanemab and donanemab. First-patient enrollment is expected before September 2026, with study completion targeted within approximately 12 months.

The ADRD study builds on the broader Imaginostics platform, which holds FDA Breakthrough Device Designation (Q242034) and is being developed for deployment across existing MRI scanners through a collaboration with Siemens Healthineers.

For more information, visit <https://imaginostics.com> or contact codi@imaginostics.com.

ImmunoBrain Presents Clinical Data for First Immune Checkpoint Therapy Approach in Alzheimer's Disease at AD/PD™ 2026

ImmunoBrain, a clinical-stage biopharmaceutical company developing novel immunotherapies for neurodegenerative diseases, today presented new data from the first clinical study in Alzheimer's disease (AD) patients, evaluating IBC-Ab002, an inhibitory immune checkpoint blockade therapeutic approach. The findings were presented by Professor Catherine J. Mummery, M.B.B.S., Ph.D., F.R.C.P., the study's lead investigator, as part of a symposium at the Alzheimer's & Parkinson's Diseases Conference (AD/PD™) 2026 in Copenhagen, Denmark.

The Phase 1b clinical trial (IBC-01-01) was a randomized, double-blind, placebo-controlled study that enrolled 40 patients with early AD across sites in the U.K., the Netherlands, and Israel. The primary and secondary endpoints of the study were safety, tolerability, and pharmacokinetics. Exploratory measures of CNS engagement included AD-related CSF biomarkers at 12 months. All immune-related adverse events were generally mild and manageable, with no serious adverse events related to the study drug and no cases of amyloid-related imaging abnormalities (ARIA). CSF biomarker analysis (Neurogranin, total-Tau, and pTau181) at a dose of 30 mg/kg of IBC-Ab002, compared to placebo, is concordant with potential synaptic and neuronal protection. Read more on [PR Newswire here](#).



Upcoming Conferences

Alzheimer's Association International Conference® (AAIC®) 2026

Registration is open for the [Alzheimer's Association International Conference® \(AAIC®\) 2026](#). Join us in London, July 12-15, 2026, to share your latest findings, exchange ideas and inspire progress alongside the global leaders advancing Alzheimer's and dementia science and clinical practice.

AABC Hybrid Meeting

The AABC will hold a hybrid meeting on Monday, July 13, 2026 at the Excel Convention Center in the Victoria 8 room. All AABC members are invited to attend virtually or in person, a calendar invite will be sent to reserve this time. If in-person, join us at the ISTAART reception on Monday, July 13 at 6:30pm at the InterContinental O2 hotel in the Arora Ballroom.



Social Media

Follow our [LinkedIn](#) page! We look forward to using the page to foster partnerships and communications.



Spread the Word

To help us grow AABC, please continue to introduce new members and companies to our group. We also welcome ideas or events for this newsletter so we can better serve you. Please send your suggestions to Ashley Hansen at (ahansen@alz.org).